Ascentage Pharma to Present Olverembatinib Data at ASH 2025
Ticker: AAPG · Form: 6-K · Filed: Nov 4, 2025 · CIK: 2023311
Sentiment: neutral
Topics: clinical-trials, data-release, pharmaceuticals, conference
TL;DR
Ascentage Pharma (001-42484) presenting new Olverembatinib data, including POLARIS-1, at ASH 2025.
AI Summary
Ascentage Pharma Group International announced on November 3, 2025, that it will present data from multiple studies of its drug Olverembatinib at the ASH 2025 conference. This includes the first dataset from the POLARIS-1 study, which focuses on the drug's efficacy in treating certain hematological malignancies.
Why It Matters
The presentation of new clinical trial data, especially from a study like POLARIS-1, is crucial for assessing the potential of Olverembatinib and could impact the company's future development and commercialization strategies.
Risk Assessment
Risk Level: medium — Clinical trial data presentations are a standard part of drug development but carry inherent risks related to trial outcomes and regulatory approval.
Key Players & Entities
- Ascentage Pharma Group International (company) — Registrant
- Olverembatinib (drug) — Drug being studied
- ASH 2025 (conference) — Event where data will be presented
- POLARIS-1 Study (study) — Specific clinical trial
- November 3, 2025 (date) — Date of press release
FAQ
What specific hematological malignancies will the POLARIS-1 study data focus on?
The filing states the data pertains to studies of Olverembatinib, including the first dataset from the POLARIS-1 Study, but does not specify the exact hematological malignancies.
When is the ASH 2025 conference scheduled to take place?
The filing does not provide the specific dates for the ASH 2025 conference, only that data will be presented there.
What is the primary purpose of presenting data at the ASH 2025 conference?
The purpose is to present data from multiple studies of Olverembatinib, including the initial findings from the POLARIS-1 study.
Is this filing related to a specific regulatory submission for Olverembatinib?
This filing is a Form 6-K reporting press releases about upcoming data presentations, not a direct regulatory submission.
Where is Ascentage Pharma Group International headquartered?
Ascentage Pharma Group International is headquartered at 68 Xinqing Road, Suzhou Industrial Park, Suzhou, Jiangsu, China.
Filing Stats: 309 words · 1 min read · ~1 pages · Grade level 13.8 · Accepted 2025-11-04 08:15:31
Filing Documents
- ea0263824-6k_ascentage.htm (6-K) — 12KB
- ea026382401ex99-1_ascentage.htm (EX-99.1) — 43KB
- ea026382401ex99-2_ascentage.htm (EX-99.2) — 48KB
- ea026382401ex99-3_ascentage.htm (EX-99.3) — 62KB
- ex99-1_001.jpg (GRAPHIC) — 10KB
- ex99-2_001.jpg (GRAPHIC) — 10KB
- ex99-3_001.jpg (GRAPHIC) — 18KB
- 0001213900-25-105632.txt ( ) — 221KB
From the Filing
OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of November 2025 Commission File Number: 001-42484 ASCENTAGE PHARMA GROUP INTERNATIONAL (Translation of Registrant’s name into English) 68 Xinqing Road Suzhou Industrial Park Suzhou, Jiangsu China (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F On November 3, 2025, Ascentage Pharma Group International (“Ascentage Pharma” or the “Company”) issued two press releases entitled, “Ascentage Pharma to Present Data from Multiple Studies of Olverembatinib, Including the First Dataset from POLARIS-1 Study, at ASH 2025” and “Ascentage Pharma to Present Data from Two Clinical Studies for Bcl-2 Inhibitor Lisaftoclax, Including an Oral Report, at ASH 2025”. A copy of the press releases are furnished as Exhibits 99.1 and 99.2 to this Report. On November 4, 2025, Ascentage Pharma Group International posted an announcement on the Hong Kong Stock Exchange entitled, “Ascentage Pharma to Present Results from Multiple Clinical Studies of olverembatinib, lisaftoclax, APG-5918 at the 2025 American Society of Hematology (ASH) Annual Meeting, one of which have been selected for Oral Reports”. A copy of the announcement is furnished as Exhibit 99.3 to this Report. 1 INDEX TO EXHIBITS Exhibit Number Exhibit Title 99.1 Press release dated November 3, 2025 99.2 Press release date November 3, 2025 99.3 Announcement dated November 4, 2025 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. ASCENTAGE PHARMA GROUP INTERNATIONAL Date: November 4, 2025 /s/ Dajun Yang Name: Dajun Yang Title: Chief Executive Officer 3